📰 Refractory Multiple News

Page 2 - Refractory Multiple News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Refractory Multiple. Real-time updates on events, politics, business and more.

Regeneron to Highlight Scientific Advancements Across

November 3, 2023

Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse...

San Diego United States Audrey Le Floch Jone Arnason Pozelimab Monotherapy Leah Sabin

Source: globenewswire.com

Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

November 3, 2023

Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse large B-cell lymphoma Additional presentations...

San Diego United States Pozelimab Monotherapy Odronextamab Monotherapy Sabarish Ram Ayyappan Qiufei Ma

Source: marketscreener.com

Elranatamab Approaches EU Approval for Heavily Pretreated Relapsed/Refractory Multiple Myeloma

November 1, 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of elranatamab-bccm for the treatment of adult patients with relapsed/refractory multiple myeloma who were previously treated with 3 or more lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and who experienced disease progression on their last therapy.

France General Chris Boshoff Mohamad Mohty Cellular Therapy Department International Myeloma Working Group European Commission

Source: onclive.com

Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

September 29, 2023

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Hong Kong United States Lugui Qiu Eli Lilly Innovent Biologics Chunrui Li

Source: prnewswire.com

IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

September 28, 2023

/PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody...

Lugui Qiu Adimab Incyte Chunrui Li Eli Lilly A Equecabtagene Autoleucel Equecabtagene Autoleucel

Source: prnewswire.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings

September 26, 2023

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

United States United Kingdom South Korea Kyongsang Bukto Hong Kong Reshma Rangwala

Source: prnewswire.com

Sustained MRD Negativity With Cilta-Cel Leads to Deep Responses in Relapsed/Refractory Multiple Myeloma

September 8, 2023

Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.

United States Yi Lin Thomasg Martin Ciltacabtagene Autoleucel Helen Diller Family Comprehensive Cancer Center Meeting Of The Society Hematologic Oncology

Source: onclive.com